Anti-PDE2A antibody R1G

  • Description

  • Application Data


Antibody raised against PDE2A, a cyclic nucleotide phosphodiesterase specific for second messengers cAMP and cGMP.

See full description

Application Data

Catalogue number crb2005716d/R1G
Antibody Anti-PDE2A antibody R1G
Antigen Peptide KLH conjugated synthetic peptide crb1200925
Protein ID UniProtKB - O00408-4
Aliases cGMP-dependent 3',5'-cyclic phosphodiesterase, Cyclic GMP-stimulated phosphodiesterase, CGS-PDE, cGSPDE
Cross-Reactivity Human
Host Species Rabbit
Antibody Type Polyclonal
Concentration 2.0 mg/ml Glycine (R1G)
Target PDE2A
Family Cyclic nucleotide phosphodiesterase family. PDE2 subfamily.
Storage This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/thaw cycles.
Material Safety Data Sheet (MSDS)

PDEs are a family of phosphohydrolyases, used to catalyse hydrolysis of 3’ cyclic phosphate bonds in the second messengers adenosine and guanine 3’, 5’ cyclic monophosphates (cAMP and cGMP). Physiologically, PDE2A is a locus for communication between cAMP and cGMP signalling pathways, regulating this process through degradation of cAMP and cGMP. This is particularly noteworthy in cells where cAMP and cGMP regulate opposing cell functions.
PDE2A is expressed both in the periphery and central nervous system, but is found in highest concentration in the brain; implying that PDE2A is necessary in regulation of interneuronal cAMP and cGMP involved in emotion, sensory perception and memory. Alteration in cyclic nucleotide signalling is shown cause depression, bipolar disorder and schizophrenia; hence PDE2A, a molecule used to break down cyclic nucleotides, has the potential to be a novel biomarker or therapeutic target for such psychiatric conditions.

Anti-PDE2A antibody R1G

Bulk Quote